How competition between Chinese and Indian firms could reshape Africa’s drug markets
China is challenging India’s long-held dominance of the African market for antimalarial drugs in 12 of the continent’s hardest-hit countries, according to a new study. Last year, Chinese exports of antimalarial drugs reached US$89.3 million, nearly matching India’s US$89.6 million, according to Indian market research company Sol Gravitas. The gap has closed significantly since 2021, when Indian…
A recent study highlights how Chinese and Indian pharmaceutical companies are contesting for dominance in Africa's antimalarial drug market. Chinese exports of antimalarial drugs reached US$89.3 million in 2022, closely matching India's US$89.6 million, according to Sol Gravitas market research. This competitive balance represents a significant shift from 2021, when India led with US$121 million compared to China's US$62.6 million.
The Global Fund, a key player in malaria programs, has increasingly purchased injectable artesunate and blister packs made in China, broadening supply options and potentially lowering prices. However, this competition could raise concerns about dependency on specific manufacturers and the future of local antimalarial research and development.
China's pharmaceutical strength, competitive pricing, and expertise in artemisinin-based medicines provide them an edge. The study underscores the importance of increasing local production and improving regulatory capabilities in Africa to ensure sustainable supply security and affordability of antimalarial drugs.
Written by urgent.news from Reuters Business via SCMP's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
